Oral Tactile Sensitivity in Stroke Patients
Launched by UNIVERSITY OF BERN · Jul 1, 2016
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Material and Methods:
Ethical approval was granted (Psy11-259, Psy 11-032) and written informed consent was obtained from all participants and/or their legal guardian. Patients were screened and recruited from the Division of Neurorehabilitation, Department of Clinical Neurosciences, University Hospital and University of Geneva, Geneva, Switzerland by a senior consultant neurologist (BL). Patients were included if they were hospitalized for stroke rehabilitation, were able to undergo psychophysical testing and presented with a facial impairment according to the House-Brackmann criteria ≥2 ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent
- • Hospitalized for stroke rehabilitation
- • Able to undergo psychophysical testing
- • Presented with a facial impairment according to the House-Brackmann criteria ≥2
- Exclusion Criteria:
- • Presented with acute pain in the oro-facial sphere (nominal question)
- • Additional neuro-muscular disease.
About University Of Bern
The University of Bern, a leading research institution in Switzerland, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university fosters an environment where scientific inquiry and clinical application intersect. Its commitment to ethical standards and patient safety ensures that all trials are conducted with the highest integrity, striving to contribute valuable insights to the global medical community. The University of Bern actively engages in diverse therapeutic areas, aiming to translate research findings into tangible health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva, , Switzerland
Patients applied
Trial Officials
Martin Schimmel, Prof
Principal Investigator
University of Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials